In October, the MHRA reviewed data from the earliest trials of Seroxat. The information was supplied by GlaxoSmithKline in the late Eighties, and it was the MHRA's responsibility to analyse the ...
The GlaxoSmithKline website was also searched for relevant studies on paroxetine. Outcome measures were the Clinical Global Impressions scale, the Children's Depression Rating Scale-Revised ...
This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy ...
MPs also heard British pharmaceutical company GSK (GlaxoSmithKline) had held back test results that linked the antidepressant paroxetine to an increased risk of child suicide. Similarly ...
The debate was told that GSK (GlaxoSmithKline) had kept back tests which showed that the antidepressant paroxetine increased the chance of children committing suicide. Likewise, in 2010 ...
Hosted on MSN20d
Deadly side effects of Ozempic being 'hidden' from patientsMPs also heard British pharmaceutical company GSK (GlaxoSmithKline) had held back test results that linked the antidepressant paroxetine to an increased risk of child suicide. Similarly ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, ...
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results